GSK's Growth Drivers And Cost Containment Offset Pandemic Impact
Immunization Rates Returning To Pre-COVID Levels
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
